Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p483 | Paediatric bone disease | ECTS2016

Loss of type I collagen telopeptide lysyl hydroxylation causes musculoskeletal abnormalities in a zebrafish model of Bruck syndrome

Willaert Andy , Ghistelinck Charlotte , Witten P Eckhard , Huysseune Ann , Simoens Pascal , Symoens Sofie , Malfait Fransiska , De Muynck Amelie , De Paepe Anne , Kwon Ronald Y , Weiss Mary Ann , Eyre David E , Coucke Paul

Bruck syndrome, a disorder caused by bi-allelic mutations in either PLOD2 or FKBP10, is characterized by flexion contractures and bone fractures and shows strong clinical overlap with the brittle bone disease Osteogenesis Imperfecta. PLOD2 encodes the Lysyl hydroxylase 2 (LH2) enzyme, which is responsible for the hydroxylation of lysine residues in the type-I collagen telopeptides. This hydroxylation directs cross-linking of the collagen fibrils in t...

ba0005lb9 | (1) | ECTS2016

First X-linked form of osteogenesis imperfecta, caused by mutations in MBTPS2, demonstrates a fundamental role for regulated intramembrane proteolysis in normal bone formation

Lindert Uschi , Cabral Wayne , Ausavarat Surasawadee , Tongkobpetch Siraprapa , Ludin Katja , Barnes Aileen , Yeetong Patra , Weis Maryann , Krabichler Birgit , Makareeva Elena , Janecke Andreas , Leikin Sergey , Rothlisberger Benno , Rohrback Marianne , Kennerknecht Ingo , Eyre David , Suphapeetiporn Kanya , Giunta Cecilia , Marini Joan , Shotelersuk Vorasuk

Osteogenesis imperfecta (OI) is a heritable bone dysplasia with collagen-related defects. Dominantly inherited OI is caused by structural defects in type I collagen or IFITM5, while recessive forms are caused by deficiency of proteins that interact with collagen for modification, folding or cross-linking. We have identified the first X-linked form of OI, caused by a defect in regulated intramembrane proteolysis (RIP). One type of RIP involves sequential cleavage of regulatory ...

ba0007p151 | (1) | ICCBH2019

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Given its convenient mode of administration, our goal was to assess the safety and efficacy of Dmab compared to intravenous zoledronic acid (ZA) in pediatric osteoporosis.Methods: In this one-year pilot study (NCT02632916), children 4–16 years with low-trauma fractures due to osteoporosis were randomized 1:1 to receive ZA 0.025 mg/kg or Dma...

ba0007p152 | (1) | ICCBH2019

An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Recent reports have raised concern about the ‘rebound phenomenon’ (hypercalcemia and increases in bone turnover markers, BTM) following Dmab in adults, and during treatment in children with osteogenesis imperfecta. The purpose of this report was to explore this phenomenon in children with osteoporosis associated with lower bone turnover.<p class="abstext...

ba0007p164 | (1) | ICCBH2019

Musculoskeletal deficits persist up to two years despite anti-TNF-alpha antibody therapy in children with Crohn's disease: Results of a prospective, observational inception cohort study

Jackowski Stefan A , Ma Jinhui , Benchimol Eric I , Rauch Frank , Leonard Mary B , Zemel Babette S , Matzinger Mary Ann , Shenouda Nazih , Lentle Brian , Jaremko Jacob L , Khatchadourian Karine , Robinson Marie-Eve , Konji Victor N , Siminoski Kerry , Mack David , Ward Leanne M

Objectives: To evaluate musculoskeletal trajectories in children with newly diagnosed Crohn’s disease (CD), and to determine whether children treated with anti-tumour necrosis factor-alpha antibody (anti-TNF, TREATED vs NAÏVE) had persistent deficits at two years.Methods: This was a single-centre prospective, observational inception cohort study. Children with CD underwent assessments within 6.5±9.5 days from diagnosis and annually for two...

ba0007lb5 | (1) | ICCBH2019

Chronic recurrent multifocal osteomyelitis in children with hypophosphatasia explained by anti-inflammatory nucleotidase activity of tissue nonspecific alkaline phosphatase in mesenchymal and hematopoietic cells

Bessueille Laurence , Briolay Anne , Como Juna , Mansouri Cylia , Gleizes Marie , El Jamal Alaeddine , Buchet Rene , Dumontet Charles , Matera Eva-Laure , Mornet Etienne , Millan Jose Luis , Fonta Caroline , Magne David

Deficiency in tissue nonspecific alkaline phosphatase (TNAP) causes hypophosphatasia (HPP), which is mainly characterized by skeletal hypomineralization. TNAP promotes mineralization by dephosphorylating the mineralization inhibitor inorganic pyrophosphate (PPi), which is generated from adenosine triphosphate (ATP) by ectonucleotide pyrophosphatase phosphodiesterase 1 (NPP1). Chronic recurrent multifocal osteomyelitis (CRMO), a sterile bone auto-inflammatory disease, has been ...

ba0003pp324 | Osteoporosis: treatment | ECTS2014

The effects of risk factors on raloxifene, alendronate, and vitamin D treatment in postmenopausal osteoporosis

Somekawa Yoshiaki , Fusegi Atsusi , Okamoto Chiaki , Sekigawa Kana , Tsugata Mikiko , Umeki Hidenori

Objective: The purpose of this study was to compare the efficacy of raloxifene (RLX) 60 mg daily, vitamin D (VD) 200 IU daily, and alendronate (ALN) 35 mg once weekly on bone mineral density (BMD) of lumbar spine (L) and total femur (F) in postmenopausal women with osteoporosis, and the effects of the osteoporosis risk factors on BMDs and these treatments.Design and methods: The subjects were 242 postmenopausal Japanese women aged 48–87 years (mean ...

ba0001pp195 | Cell biology: osteoblasts and bone formation | ECTS2013

Microarray reveals positive effects of green and black tea polyphenols on TNFα-induced changes of gene expression

Zulkipli Husna , Salim Norita , Froemming Gabriele Anisah , Ismail Aletza Mohd , Nawawi Hapizah

Introduction: Recent studies have found anti-inflammatory, antioxidant and bone forming properties of green (GTP) and black tea (BTP) polyphenols. However most of these studies are focussed on specific genes or pathways. We wanted to know if GTP and BTP could help to reduce symptoms of chronic inflammation especially bone loss and what are the possible genes and pathways involved. We were especially interested in unexplored pathways which may play a role in regaining bone heal...

ba0005p189 | Cell biology: osteoclasts and bone resorption | ECTS2016

Pathophysiological implication of Autotaxin on osteoclast function

Flammier Sacha , Gicquel Tristan , Duboeuf Francois , Peyruchaud Olivier , Coury Fabienne , Machuca-Gayet Irma

Autotaxin (ATX) is a secreted protein produced by various tissues in the body including the liver, adipose tissue and bone. Autotaxin (ATX) is an enzyme with a phospholipase D activity responsible for cleavage of lysophosphatidyl-choline (LPC) in lysophosphatidic acid (LPA). LPA is a bio phospholipid, which acts as a growth factor, affecting proliferation, differentiation, and migration. It has been shown that the biological effect of LPA could be the direct consequence of loc...